tiprankstipranks
Heron Therapeutics Inc (DE:AXD2)
NASDAQ:AXD2
Germany Market
AXD2
Heron Therapeutics
RESEARCH TOOLSreports

Heron Therapeutics (AXD2) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

AXD2 Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Heron
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXD2 Stock 12 Month Forecast

Average Price Target

€1.73
▲(121.51% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Heron Therapeutics in the last 3 months. The average price target is €1.73 with a high forecast of €1.73 and a low forecast of €1.73. The average price target represents a 121.51% change from the last price of €0.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.72780804,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.72780804,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.72780804,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.73</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.737,0.8132160030769231,0.8894320061538461,0.9656480092307692,1.0418640123076923,1.1180800153846153,1.1942960184615385,1.2705120215384615,1.3467280246153845,1.4229440276923078,1.499160030769231,1.5753760338461538,1.651592036923077,{"y":1.72780804,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.737,0.8132160030769231,0.8894320061538461,0.9656480092307692,1.0418640123076923,1.1180800153846153,1.1942960184615385,1.2705120215384615,1.3467280246153845,1.4229440276923078,1.499160030769231,1.5753760338461538,1.651592036923077,{"y":1.72780804,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.737,0.8132160030769231,0.8894320061538461,0.9656480092307692,1.0418640123076923,1.1180800153846153,1.1942960184615385,1.2705120215384615,1.3467280246153845,1.4229440276923078,1.499160030769231,1.5753760338461538,1.651592036923077,{"y":1.72780804,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.628,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.725,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.061,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.008,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.981,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.092,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.093,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.001,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.688,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.998,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.737,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€1.73Average Price Target€1.73Lowest Price Target€1.73
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:AXD2
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€1.73
Buy
121.51%
Upside
Reiterated
06/08/26
Heron Therapeutics (HRTX) Receives a Buy from H.C. Wainwright
Needham Analyst forecast on DE:AXD2
Serge Belanger
Needham
Needham
―
Hold
―
Downgraded
06/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (NASDAQ: HRTX) and Praxis Precision Medicines (NASDAQ: PRAX)
Northland Securities Analyst forecast on DE:AXD2
Carl Byrnes
Northland Securities
Northland Securities
€3.46
Buy
343.03%
Upside
Reiterated
11/05/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on DE:AXD2
Clara Dong
Jefferies
Jefferies
€4.32
Buy
453.78%
Upside
Reiterated
11/04/25
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:AXD2
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€1.73
Buy
121.51%
Upside
Reiterated
06/08/26
Heron Therapeutics (HRTX) Receives a Buy from H.C. Wainwright
Needham Analyst forecast on DE:AXD2
Serge Belanger
Needham
Needham
―
Hold
―
Downgraded
06/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (NASDAQ: HRTX) and Praxis Precision Medicines (NASDAQ: PRAX)
Northland Securities Analyst forecast on DE:AXD2
Carl Byrnes
Northland Securities
Northland Securities
€3.46
Buy
343.03%
Upside
Reiterated
11/05/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on DE:AXD2
Clara Dong
Jefferies
Jefferies
€4.32
Buy
453.78%
Upside
Reiterated
11/04/25
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Heron Therapeutics

3 Months
Carl ByrnesNorthland Securities
Success Rate
15/31 ratings generated profit
48%
Average Return
+1.37%
Copying Carl Byrnes's trades and holding each position for 3 Months would result in 48.39% of your transactions generating a profit, with an average return of +1.37% per trade.
1 Year
Carl ByrnesNorthland Securities
Success Rate
4/31 ratings generated profit
13%
Average Return
-28.77%
Copying Carl Byrnes's trades and holding each position for 1 Year would result in 12.90% of your transactions generating a profit, with an average return of -28.77% per trade.
2 Years
Carl ByrnesNorthland Securities
Success Rate
2/31 ratings generated profit
6%
Average Return
-57.68%
Copying Carl Byrnes's trades and holding each position for 2 Years would result in 6.45% of your transactions generating a profit, with an average return of -57.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXD2 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
5
5
5
6
8
Buy
0
0
0
0
0
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
5
6
9
In the current month, AXD2 has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AXD2 average Analyst price target in the past 3 months is 1.73.
Each month's total comprises the sum of three months' worth of ratings.

AXD2 Financial Forecast

AXD2 Earnings Forecast

Next quarter’s earnings estimate for AXD2 is >-€0.01 with a range of -€0.02 to <€0.01. The previous quarter’s EPS was -€0.03. AXD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXD2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for AXD2 is >-€0.01 with a range of -€0.02 to <€0.01. The previous quarter’s EPS was -€0.03. AXD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXD2 has Performed in-line its overall industry.

AXD2 Sales Forecast

Next quarter’s sales forecast for AXD2 is €36.17M with a range of €36.04M to €36.40M. The previous quarter’s sales results were €29.80M. AXD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXD2 has Performed in-line its overall industry.
Next quarter’s sales forecast for AXD2 is €36.17M with a range of €36.04M to €36.40M. The previous quarter’s sales results were €29.80M. AXD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXD2 has Performed in-line its overall industry.

AXD2 Stock Forecast FAQ

What is DE:AXD2’s average 12-month price target, according to analysts?
Based on analyst ratings, Heron Therapeutics Inc’s 12-month average price target is 1.73.
    What is DE:AXD2’s upside potential, based on the analysts’ average price target?
    Heron Therapeutics Inc has 121.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Heron Therapeutics Inc a Buy, Sell or Hold?
          Heron Therapeutics Inc has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Heron Therapeutics Inc’s share price target?
            The average share price target for Heron Therapeutics Inc is 1.73. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €1.73 ,and the lowest forecast is €1.73. The average share price target represents 121.51% Increase from the current price of €0.78.
              What do analysts say about Heron Therapeutics Inc?
              Heron Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Heron Therapeutics Inc?
                To buy shares of DE:AXD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.